James Cummings
Hoofd Techniek/Wetenschap/O&O bij VAXART, INC.
Vermogen: 215 035 $ op 30-04-2024
Profiel
James F.
Cummings is currently the Chief Medical Officer at Vaxart, Inc. Prior to this, he served as the President & CEO at ICON Government & Public Health Solutions, Inc. from 2018 to 2021.
He also held positions as Director at OyaGen, Inc., Director-Translational Medicine at Walter Reed Army Institute of Research from 2007 to 2009, Director-Defense Department at Global Emerging Infectious Surveillance & Response System from 2012 to 2015, and VP-Clinical Development & Translational Medicine at Novavax, Inc. from 2015 to 2018.
Cummings received his undergraduate degree from Georgetown University School of Medicine.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
VAXART, INC.
0.18% | 28-03-2024 | 326 801 ( 0.18% ) | 215 035 $ | 30-04-2024 |
Actieve functies van James Cummings
| Bedrijven | Functie | Begin |
|---|---|---|
| VAXART, INC. | Hoofd Techniek/Wetenschap/O&O | 27-09-2021 |
Eerdere bekende functies van James Cummings
| Bedrijven | Functie | Einde |
|---|---|---|
ICON Government & Public Health Solutions, Inc.
 ICON Government & Public Health Solutions, Inc. Miscellaneous Commercial ServicesCommercial Services ICON Government & Public Health Solutions, Inc. operates as a full service Contract Research Organization (CRO) specializing in preclinical through Phase IV support of clinical research and clinical trial services for biologics, drugs, and devices. Its services include project, program, and data management; clinical monitoring; regulatory and medical affairs; and safety oversight and pharmacovigilance. The company was founded by Victoria Tifft in 1994 and is headquartered in Hinckley, OH. | Algemeen Directeur | 01-09-2021 |
| NOVAVAX, INC. | Hoofd Techniek/Wetenschap/O&O | 01-01-2018 |
| Global Emerging Infectious Surveillance & Response System | Corporate Officer/Principal | 01-08-2015 |
| Walter Reed Army Institute of Research | Corporate Officer/Principal | 01-03-2009 |
OyaGen, Inc.
 OyaGen, Inc. Pharmaceuticals: MajorHealth Technology OyaGen, Inc. operates as a biotechnology company. It offers anti Human Immunodeficiency Virus (HIV) drug that solves the problems of viral resistance. The company was founded by Harold Smith in September 2003 and is headquartered in Henrietta, NY. | Directeur/Bestuurslid | - |
Opleiding van James Cummings
| Georgetown University School of Medicine | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| NOVAVAX, INC. | Health Technology |
| VAXART, INC. | Health Technology |
| Bedrijven in privébezit | 4 |
|---|---|
ICON Government & Public Health Solutions, Inc.
ICON Government & Public Health Solutions, Inc. Miscellaneous Commercial ServicesCommercial Services ICON Government & Public Health Solutions, Inc. operates as a full service Contract Research Organization (CRO) specializing in preclinical through Phase IV support of clinical research and clinical trial services for biologics, drugs, and devices. Its services include project, program, and data management; clinical monitoring; regulatory and medical affairs; and safety oversight and pharmacovigilance. The company was founded by Victoria Tifft in 1994 and is headquartered in Hinckley, OH. | Commercial Services |
OyaGen, Inc.
OyaGen, Inc. Pharmaceuticals: MajorHealth Technology OyaGen, Inc. operates as a biotechnology company. It offers anti Human Immunodeficiency Virus (HIV) drug that solves the problems of viral resistance. The company was founded by Harold Smith in September 2003 and is headquartered in Henrietta, NY. | Health Technology |
| Walter Reed Army Institute of Research | |
| Global Emerging Infectious Surveillance & Response System |
